DNA-binding domain of CRISPR system, non-fucosylated and partially fucosylated proteins, and methods thereof

US11548937B2 · kind B2 · utility

Assignee

• Zumutor Biologics Inc. · US

Inventors

• Bhargav Prasad · Komangalam, IN
• Divya Unnikrishnan · Kanchinakote, IN
• Jahnabi Hazarika · Kanchinakote, IN
• Kavitha Iyer Rodrigues · Bengaluru, IN
• Maloy Ghosh · Kanchinakote, IN
• Pavithra M · Kundapura, IN
• Pravin Kumar D · Chennai, IN
• Sanghamitra Bhattacharjee · Kanchinakote, IN
• Sathyabalan M · Bengaluru, IN
• Sankaranarayanan Srinivasan · Kanchinakote, IN
• Sohang Chatterjee · Kanchinakote, IN
• Sunit Maity · Kanchinakote, IN
• Veeresha K · Kanchinakote, IN
• Vivek Halan · Viralimalai, IN
• Yogendra Manjunath B. M. · Bengaluru, IN
• Anuradha Hora · Sitapur, IN
• Bairavabalakumar N · Chennai, IN
• Karthika Nair · Survanagiri, IN
• Aswini Thanigaivel · Chennai, IN
• Amol Maliwalave · Survanagiri, IN
• Bharath Ravindra Shenoy · Kanchinakote, IN
• Rajeshwari Pendse · Bengaluru, IN
• Prabhat Kumar Pathak · Varanasi, IN
• Anisha Kurup · Delhi, IN
• Sahana Bhima Rao · Kanchinakote, IN

Key dates

• Filing date: Jul 6, 2020
• Grant date: Jan 10, 2023
• Expiry date: Apr 1, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to a method of obtaining a cell where fucosylation pathways are modified, leading to production of partially fucosylated and non-fucosylated protein products, specifically antibodies from the cell. The present disclosure employs the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. The method of the present disclosure targets the Fut8 gene and GMD gene in a cell. Such products are used in developing therapeutics and biomarkers, and in diagnosis and prognosis of diseases.